Arcoma AB (ARCOMA) - Total Assets
Based on the latest financial reports, Arcoma AB (ARCOMA) holds total assets worth Skr97.97 Million SEK (≈ $10.54 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ARCOMA total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Arcoma AB - Total Assets Trend (2012–2024)
This chart illustrates how Arcoma AB's total assets have evolved over time, based on quarterly financial data. Check ARCOMA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Arcoma AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Arcoma AB's total assets of Skr97.97 Million consist of 71.3% current assets and 28.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 16.6% |
| Accounts Receivable | Skr17.47 Million | 21.7% |
| Inventory | Skr23.94 Million | 29.8% |
| Property, Plant & Equipment | Skr1.14 Million | 1.4% |
| Intangible Assets | Skr18.49 Million | 23.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Arcoma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ARCOMA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arcoma AB's current assets represent 71.3% of total assets in 2024, an increase from 67.3% in 2012.
- Cash Position: Cash and equivalents constituted 16.6% of total assets in 2024, up from 0.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 21.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 29.8% of total assets.
Arcoma AB Competitors by Total Assets
Key competitors of Arcoma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
Arcoma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.14 | 2.20 | 1.37 |
| Quick Ratio | 2.04 | 1.24 | 0.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr52.60 Million | Skr33.84 Million | Skr15.70 Million |
Arcoma AB - Advanced Valuation Insights
This section examines the relationship between Arcoma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.52 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -1.8% |
| Total Assets | Skr80.46 Million |
| Market Capitalization | $13.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Arcoma AB's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Arcoma AB's assets decreased by 1.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Arcoma AB (2012–2024)
The table below shows the annual total assets of Arcoma AB from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr80.46 Million ≈ $8.66 Million |
-1.83% |
| 2023-12-31 | Skr81.96 Million ≈ $8.82 Million |
-18.31% |
| 2022-12-31 | Skr100.33 Million ≈ $10.80 Million |
+26.57% |
| 2021-12-31 | Skr79.27 Million ≈ $8.53 Million |
-16.59% |
| 2020-12-31 | Skr95.03 Million ≈ $10.23 Million |
+14.04% |
| 2019-12-31 | Skr83.33 Million ≈ $8.97 Million |
+9.25% |
| 2018-12-31 | Skr76.27 Million ≈ $8.21 Million |
+11.98% |
| 2017-12-31 | Skr68.11 Million ≈ $7.33 Million |
-4.41% |
| 2016-12-31 | Skr71.25 Million ≈ $7.67 Million |
-15.43% |
| 2015-12-31 | Skr84.25 Million ≈ $9.07 Million |
+6.37% |
| 2014-12-31 | Skr79.21 Million ≈ $8.52 Million |
+11.77% |
| 2013-12-31 | Skr70.87 Million ≈ $7.63 Million |
+3.47% |
| 2012-12-31 | Skr68.49 Million ≈ $7.37 Million |
-- |
About Arcoma AB
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank; and accessories for x-ray equipment comprising live camera, advanc… Read more